EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Institute Curie
París, FranciaPublicaciones en colaboración con investigadores/as de Institute Curie (4)
2021
2020
-
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 26, Núm. 15, pp. 3947-3957
-
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Annals of Oncology, Vol. 31, Núm. 8, pp. 1001-1010
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710